CPRX

CATALYST PHARMACEUTICALS INC

CPRX·14888U101·US·Common Stock·Healthcare - Biotechnology-13D/G

CPRX (CATALYST PHARMACEUTICALS INC) is held by 162 institutional investors as of Q2 2026. Largest holders: BlackRock, Inc. ($602.2M), STATE STREET CORP ($239.7M), AMERICAN CENTURY COMPANIES INC ($174.6M). Net institutional sentiment: Mixed.

162
Holders
(11 Elite)
$2.7B
Total Value
48% (178)
Consensus
86 buying - 92 selling
13F: Insider & Congress: Updated regularly
CPRX

Smart Money Verdict

View all
Loading verdict
Held by 162 funds
11 elite

Who's Trading

Source dates: Price Jul 21, 2026 · Insiders Dec 16, 2025 · Activists Mar 26, 2026 · Congress none

ActivistThe Vanguard GroupThe Vanguard Group0.0%Mar 26, 2026
InsiderHMHarper MollySell $360KDec 12, 2025
InsiderHMHarper MollySell $156KDec 12, 2025
Checking access…

Top Holders

Checking access…
Fund
Action
Shares
Value
Weight
Est. P&L
Conviction
Increased
19.2M(+2.0%)$602.2M0.0%+47.49%
32
Increased
7.6M(+11.1%)$239.7M0.0%+65.86%
34
Increased
5.6M(+34.2%)$174.6M0.1%+29.12%
39
Increased
5.1M(+0.3%)$161.4M0.0%+31.55%
30
Increased
3.6M(+6.0%)$114.2M0.0%+61.45%
32
Increased
3.2M(+579.0%)$99.9M0.0%+5.23%
48
Increased
3.2M(+6.0%)$99M0.0%+193.15%
32
New
2.8M$88.6M0.9%+0.19%
58
Increased
2.8M(+2.7%)$86.8M0.0%+48.91%
31
Decreased
2.4M(-1.9%)$76.3M0.0%+31.65%
0
Increased
2.3M(+446.3%)$70.9M0.1%+7.23%
48
Decreased
2.1M(-9.0%)$67.1M0.1%+97.24%
0
Decreased
1.7M(-3.1%)$52.2M0.0%+72.09%
0
Increased
1.5M(+47.4%)$45.7M0.0%+28.55%
40
Increased
1.3M(+7.5%)$41.8M0.0%+243.71%
31
Decreased
1.3M(-56.8%)$41.2M0.0%+41.56%
0
Increased
1.2M(+21.3%)$37.5M0.0%+35.65%
35
Decreased
1.2M(-18.9%)$36.4M0.0%+168.92%
0
Increased
1.1M(+39.3%)$33.6M0.0%+38.30%
38
Increased
911,700(+351.8%)$28.7M0.0%+5.90%
46

Showing 1-20 of 191

1 / 10
CPRXCPRXCATALYST PHARMACEUTICALS INC

Other Healthcare stocks held by institutions

Data sourced from four public-disclosure sources: SEC 13F, Form 4, 13D/13G, and House/Senate STOCK Act disclosures. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used